evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

4,534 questions · 5,247 findings · 456 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 1,142 · 21.8%GRADE not reported 1,503 · 28.6%Very low 1,040 · 19.8%Low 869 · 16.6%Moderate 554 · 10.6%High 139 · 2.6%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Dementia (any type or severity) vs Older people without dementia

Orofacial pain (prevalence) · Older people (aged 60 years or older) with dementia

Orofacial pain prevalence was similar in older people with dementia (7.4 to 21.7%) and without dementia (6.7 to 18.5%), based on few studies; no meta-analysis was performed (ungraded).

1 finding from 1 review

Dementia (any type or severity) vs Older people without dementia

Coronal caries (mean number) · Older people (aged 60 years or older) with dementia

Coronal caries was higher in older people with dementia (0.1 to 2.9) than without (0.0 to 1.0), described as significantly more common but not pooled (ungraded).

1 finding from 1 review

Subcutaneous unfractionated heparin vs unfractionated heparin

Symptomatic recurrent VTE at 3 months · people aged ≥ 18 years with a diagnosis of new or recurrent VTE

Subcutaneous unfractionated heparin showed no clear difference in symptomatic recurrent VTE at 3 months compared with intravenous unfractionated heparin (low certainty).

1 finding from 1 review

Subcutaneous unfractionated heparin vs low molecular weight heparin

VTE‐related mortality4 · people aged ≥ 18 years with a diagnosis of new or recurrent VTE

Subcutaneous unfractionated heparin showed no clear difference in VTE‐related mortality at 3 months compared with low molecular weight heparin (low certainty).

1 finding from 1 review

Subcutaneous unfractionated heparin vs low molecular weight heparin

Major bleedingd (3 months) · people aged ≥ 18 years with a diagnosis of new or recurrent VTE

Subcutaneous unfractionated heparin showed no clear difference in major bleedingd (3 months) compared with low molecular weight heparin (low certainty).

1 finding from 1 review

Subcutaneous unfractionated heparin vs low molecular weight heparin

All‐cause mortality (7 days ‐ 3 months) · people aged ≥ 18 years with a diagnosis of new or recurrent VTE

Subcutaneous unfractionated heparin showed no clear difference in all‐cause mortality (7 days ‐ 3 months) compared with low molecular weight heparin (low certainty).

1 finding from 1 review

Subcutaneous unfractionated heparin vs unfractionated heparin

Symptomatic recurrent DVT at 3 months · people aged ≥ 18 years with a diagnosis of new or recurrent VTE

Subcutaneous unfractionated heparin showed no clear difference in symptomatic recurrent DVT at 3 months compared with intravenous unfractionated heparin (low certainty).

1 finding from 1 review

Subcutaneous unfractionated heparin vs unfractionated heparin

VTE‐related mortality4 · people aged ≥ 18 years with a diagnosis of new or recurrent VTE

Subcutaneous unfractionated heparin showed no clear difference in VTE‐related mortality at 3 months compared with intravenous unfractionated heparin (low certainty).

1 finding from 1 review

Subcutaneous unfractionated heparin vs unfractionated heparin

Major bleedingd (3 months) · people aged ≥ 18 years with a diagnosis of new or recurrent VTE

Subcutaneous unfractionated heparin showed no clear difference in major bleedingd (7 days ‐ 12 months) compared with intravenous unfractionated heparin (low certainty).

1 finding from 1 review

Subcutaneous unfractionated heparin vs unfractionated heparin

All‐cause mortality (5 days to 12 months) · people aged ≥ 18 years with a diagnosis of new or recurrent VTE

Subcutaneous unfractionated heparin showed no clear difference in all‐cause mortality (5 days to 12 months) compared with intravenous unfractionated heparin (low certainty).

1 finding from 1 review

Subcutaneous unfractionated heparin vs low molecular weight heparin

Symptomatic recurrent VTE at 3 months · people aged ≥ 18 years with a diagnosis of new or recurrent VTE

Subcutaneous unfractionated heparin showed no clear difference in symptomatic recurrent VTE at 3 months compared with low molecular weight heparin (low certainty).

1 finding from 1 review

Subcutaneous unfractionated heparin vs low molecular weight heparin

Symptomatic recurrent DVT at 3 months · people aged ≥ 18 years with a diagnosis of new or recurrent VTE

Subcutaneous unfractionated heparin showed no clear difference in symptomatic recurrent DVT at 3 months compared with low molecular weight heparin (low certainty).

1 finding from 1 review

Intervention not reported

Smoking uptake at longest · Children and adolescents aged 5 ‐ 18 years who were non‐smokers at baseline

The intervention showed no clear difference in smoking uptake at longest (low certainty).

1 finding from 1 review

Intervention not reported

Smoking uptake at longest · Children and adolescents aged 5 ‐ 18 years who were non‐smokers at baseline

It is very uncertain whether the intervention changes smoking uptake at longest (very low certainty).

1 finding from 1 review